# Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

> **NCT06429904** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 31 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Nimotuzumab+ NALIRIFOX

## Key facts

- **NCT ID:** NCT06429904
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06429904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06429904, "Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06429904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*